Endotoxemia and Platelets: 2 Players of Intrahepatic Microthrombosis in NAFLD

Overview

Journal JACC Basic Transl Sci

Date 2024 Apr 1

PMID 38559621

Authors

Francesco Violi

Daniele Pastori

Pasquale Pignatelli

Vittoria Cammisotto

Affiliations

Soon will be listed here.

Abstract

Gut dysbiosis-related intestinal barrier dysfunction with increased translocation of bacterial products such as lipopolysaccharide (LPS) into systemic circulation is emerging as pathogenic factor of nonalcoholic fatty liver disease (NAFLD). Experimental and clinical studies suggested a potential role of LPS as a trigger eliciting in situ liver inflammation upon interaction with its receptor toll-like receptor 4. Also, LPS has been reported to prime platelets to respond to the common agonists indicating that it behaves as a prothrombotic molecule. Of note, recent studies suggested platelet-related intrahepatic thrombosis triggered by LPS as a mechanism implicated in the process of liver inflammation. This review describes: 1) the impact of gut barrier dysfunction and endotoxemia in the process of NAFLD; 2) the relationship between endotoxemia and platelet activation in NAFLD; 3) clinical evidence for the use of antiplatelet drugs in NAFLD/nonalcoholic steatohepatitis patients; and 4) the potential therapeutic approach to modulate endotoxemia and eventually platelet activation.

References

Lee T, Wu J, Yu S, Lin J, Wu M, Wu C . The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. Int J Cancer. 2017; 141(7):1307-1314. DOI: 10.1002/ijc.30784. View

Thongtan T, Deb A, Vutthikraivit W, Laoveeravat P, Mingbunjerdsuk T, Islam S . Antiplatelet therapy associated with lower prevalence of advanced liver fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Indian J Gastroenterol. 2022; 41(2):119-126. DOI: 10.1007/s12664-021-01230-3. View

Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H . Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut. 2008; 57(11):1583-91. DOI: 10.1136/gut.2007.144550. View

Queck A, Carnevale R, Uschner F, Schierwagen R, Klein S, Jansen C . Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS. Gut. 2019; 69(8):1535-1536. PMC: 7398461. DOI: 10.1136/gutjnl-2019-319044. View

Huang D, El-Serag H, Loomba R . Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2020; 18(4):223-238. PMC: 8016738. DOI: 10.1038/s41575-020-00381-6. View

Camerer E, Huang W, Coughlin S . Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci U S A. 2000; 97(10):5255-60. PMC: 25815. DOI: 10.1073/pnas.97.10.5255. View

Simon T, Henson J, Osganian S, Masia R, Chan A, Chung R . Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019; 17(13):2776-2784.e4. PMC: 6842070. DOI: 10.1016/j.cgh.2019.04.061. View

Carpino G, Ben M, Pastori D, Carnevale R, Baratta F, Overi D . Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. Hepatology. 2019; 72(2):470-485. DOI: 10.1002/hep.31056. View

Lange N, Radu P, Dufour J . Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. J Hepatol. 2021; 75(5):1217-1227. DOI: 10.1016/j.jhep.2021.07.025. View

10.

Anstee Q, Goldin R, Wright M, Martinelli A, Cox R, Thursz M . Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies. J Thromb Haemost. 2008; 6(8):1336-43. DOI: 10.1111/j.1538-7836.2008.03015.x. View

11.

Dalbeni A, Castelli M, Zoncape M, Minuz P, Sacerdoti D . Platelets in Non-alcoholic Fatty Liver Disease. Front Pharmacol. 2022; 13:842636. PMC: 8895200. DOI: 10.3389/fphar.2022.842636. View

12.

Violi F, Pignatelli P, Castellani V, Carnevale R, Cammisotto V . Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis. Blood Rev. 2022; 57:100998. DOI: 10.1016/j.blre.2022.100998. View

13.

Fukui H . Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol. 2015; 7(3):425-42. PMC: 4381167. DOI: 10.4254/wjh.v7.i3.425. View

14.

Han Y, Onufer E, Huang L, Sprung R, Davidson W, Czepielewski R . Enterically derived high-density lipoprotein restrains liver injury through the portal vein. Science. 2021; 373(6553). PMC: 8478306. DOI: 10.1126/science.abe6729. View

15.

Ghosh S, Whitley C, Haribabu B, Jala V . Regulation of Intestinal Barrier Function by Microbial Metabolites. Cell Mol Gastroenterol Hepatol. 2021; 11(5):1463-1482. PMC: 8025057. DOI: 10.1016/j.jcmgh.2021.02.007. View

16.

Turner N, Nolasco L, Tao Z, Dong J, Moake J . Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4(6):1396-404. DOI: 10.1111/j.1538-7836.2006.01959.x. View

17.

Zanetto A, Campello E, Bulato C, Gavasso S, Farinati F, Russo F . Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. J Hepatol. 2022; 77(3):660-669. DOI: 10.1016/j.jhep.2022.03.009. View

18.

Geys L, Bauters D, Roose E, Tersteeg C, Vanhoorelbeke K, Hoylaerts M . ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis. Thromb Haemost. 2016; 117(1):19-26. DOI: 10.1160/TH16-03-0195. View

19.

Violi F, Cammisotto V, Bartimoccia S, Pignatelli P, Carnevale R, Nocella C . Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nat Rev Cardiol. 2022; 20(1):24-37. PMC: 9284488. DOI: 10.1038/s41569-022-00737-2. View

20.

An L, Wirth U, Koch D, Schirren M, Drefs M, Koliogiannis D . The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. J Gastrointest Surg. 2021; 26(3):671-683. PMC: 8926958. DOI: 10.1007/s11605-021-05188-7. View